Spitzer squeezing secondary market
Executive Summary
Cardinal Health is the first wholesaler to settle with the New York Attorney General's office regarding trading in the secondary wholesale market. According to the AG's office, Cardinal bought and sold drugs in the secondary market without appropriate regard for drug integrity and risk of diversion. Under the settlement, Cardinal agrees to pay $10 million and adopt a set of Wholesaler Safe Product Practices. The investigation into improper trading practices of other wholesalers will continue, the AG says. AmerisourceBergen and McKesson have also been subpoenaed as part of the investigation (1"The Pink Sheet" April 18, 2005, p. 23). Wholesaler distribution practices that allow drug diversion may emerge as a focus of prosecution at the federal level as well (2"The Pink Sheet" Dec. 12, 2005, p. 25)...
You may also be interested in...
Appeals Court Blocks Pedigree Rule Targeting Secondary Wholesalers
FDA's long-standing but never implemented rule to require that secondary wholesalers provide a pedigree documenting prescription drugs' chain of custody has once again been rejected by the courts
Wholesalers Drawing DoJ Scrutiny In Drug Diversion Investigations
Wholesalers will face increasing Justice Department scrutiny in pharmaceutical diversion cases, a federal prosecutor predicted
Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market
AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals